BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio

Reuters12-12

Dec 12 (Reuters) - Arcus Biosciences Inc RCUS.N:

ARCUS PROVIDES UPDATE ON PHASE 3 STAR-221 STUDY AND CONCENTRATES ITS RESEARCH AND DEVELOPMENT INVESTMENT ON CASDATIFAN AND EMERGING INFLAMMATION AND IMMUNOLOGY PORTFOLIO
ARCUS BIOSCIENCES INC: STAR-221 AND PHASE 2 EDGE-GASTRIC STUDIES WILL BE DISCONTINUED
ARCUS BIOSCIENCES INC - CONTINUES TO EXPAND CASDATIFAN PROGRAM WITH DATA READOUTS IN 2026

Source text: ID:nBw1ppr59a

Further company coverage: RCUS.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590501926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590501926","market":"nz","top_or_hot":-1,"title":"BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio</title></head><body><p><span>Dec 12 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences</a> Inc <span>RCUS.N</span>:</p><ul><li><p>ARCUS PROVIDES UPDATE ON PHASE 3 STAR-221 STUDY AND CONCENTRATES ITS RESEARCH AND DEVELOPMENT INVESTMENT ON CASDATIFAN AND EMERGING INFLAMMATION AND IMMUNOLOGY PORTFOLIO</p></li><li><p>ARCUS BIOSCIENCES INC: STAR-221 AND PHASE 2 EDGE-GASTRIC STUDIES WILL BE DISCONTINUED</p></li><li><p>ARCUS BIOSCIENCES INC - CONTINUES TO EXPAND CASDATIFAN PROGRAM WITH DATA READOUTS IN 2026</p></li></ul><p>Source text: <span>ID:nBw1ppr59a</span></p><p>Further company coverage: <span>RCUS.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio</title></head><body><p><span>Dec 12 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences</a> Inc <span>RCUS.N</span>:</p><ul><li><p>ARCUS PROVIDES UPDATE ON PHASE 3 STAR-221 STUDY AND CONCENTRATES ITS RESEARCH AND DEVELOPMENT INVESTMENT ON CASDATIFAN AND EMERGING INFLAMMATION AND IMMUNOLOGY PORTFOLIO</p></li><li><p>ARCUS BIOSCIENCES INC: STAR-221 AND PHASE 2 EDGE-GASTRIC STUDIES WILL BE DISCONTINUED</p></li><li><p>ARCUS BIOSCIENCES INC - CONTINUES TO EXPAND CASDATIFAN PROGRAM WITH DATA READOUTS IN 2026</p></li></ul><p>Source text: <span>ID:nBw1ppr59a</span></p><p>Further company coverage: <span>RCUS.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3B42.SGD","symbol_name":"Legg Mason ClearBridge - Value A Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUAGYNPZ:1","article_id":"2590501926","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590501926","pubTimestamp":1765546793,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology PortfolioDec 12 (Reuters) - Arcus ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4566":"资本集团","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4578":"CAR-T","GILD":"吉利德科学","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","RCUS":"Arcus Biosciences Inc.","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","BK4583":"猴痘概念","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BK4532":"文艺复兴科技持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4585":"ETF&股票定投概念"},"translate_title":"简介-Arcus提供3期STAR-221研究的最新情况，并将研发投资集中在Casdatifan和新兴炎症和免疫学产品组合上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9,"RCUS":0.9},"content_text":"BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology PortfolioDec 12 (Reuters) - Arcus Biosciences Inc RCUS.N:ARCUS PROVIDES UPDATE ON PHASE 3 STAR-221 STUDY AND CONCENTRATES ITS RESEARCH AND DEVELOPMENT INVESTMENT ON CASDATIFAN AND EMERGING INFLAMMATION AND IMMUNOLOGY PORTFOLIOARCUS BIOSCIENCES INC: STAR-221 AND PHASE 2 EDGE-GASTRIC STUDIES WILL BE DISCONTINUEDARCUS BIOSCIENCES INC - CONTINUES TO EXPAND CASDATIFAN PROGRAM WITH DATA READOUTS IN 2026Source text: ID:nBw1ppr59aFurther company coverage: RCUS.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590501926","isCrawlerRequest":true}